Clinical Trial Update: A Trial of Tadalafil and Glycemic Traits [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tadalafil for glycemic traits in cardiovascular disease and insulin resistance has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Glucose Intolerance
• Insulin Resistance
• Obesity

Drugs mentioned

• TADALAFIL (TADALAFIL)

Snippet

Sponsor: Thomas J. Wang, MD | Conditions: Cardiovascular Disease, Insulin Resistance | Phase 3 | Status: COMPLETED | Results posted: 2017-01-30